The CCTS Drug Discovery and Development (D3) Core facilitates translational research at the University of Kentucky with an emphasis on preclinical probe/lead discovery and validation. D3 provides services, state-of-the-art facilities, unique expertise, pilot funding and educational programs to support and advance target identification/validation and novel probe/lead discovery and development.
D3 leverages the infrastructure and Computational, Synthesis, and Translational Research Support Cores of the UK Center for Pharmaceutical Research and Innovation (CPRI) to support CCTS translational research projects. CPRI evolved into an NIGMS-supported P20 Center of Biomedical Research Excellence (COBRE) and will complement and leverage existing CCTS faculty mentorship infrastructure with an emphasis on ‘translational chemical biology’.
The Computational Core provides consultation, software, and expertise to support virtual screening, predictive toxicology, computational modeling of drug-target interactions, and ligand design. We use a variety of state-of-the-art molecular modeling, stimulation, and computational techniques.
Learn more about services and related publications of this research support core.
The Synthesis Core provides consultation, reagents and equipment for the synthesis of small molecules to support the identification, development and application of novel probes and hits/leads
The Translational Core provides consultation, compound libraries, and expertise to support biochemical, cell-based, and whole animal assay development and screening for probe/hit discovery and optimization. The core also supports preliminary hit/lead in vitro and in vivo evaluation with a particular focus on microsomal metabolism, pharmacokinetics (PK), pharmacodynamics (PD), and basic toxicology (MTD).